May 19th 2017EP. 1: Understanding Age-Related Macular Degeneration
May 19th 2017EP. 2: Stages of Progression in Age-Related Macular Degeneration
May 19th 2017EP. 3: Payer Challenges in the Management of Wet AMD
May 19th 2017EP. 4: Addressing Underrecognition of Wet AMD
May 19th 2017EP. 5: AMD: Benefits of Screening and Early Diagnosis
May 19th 2017EP. 6: When a Retina Specialist Is Needed for Eye Care
May 19th 2017EP. 7: Goals of Therapy in Wet Age-Related Macular Degeneration
May 19th 2017EP. 8: Wet AMD: Understanding the Role of Anti-VEGF Therapy
May 19th 2017EP. 9: Deciding Among Anti-VEGF Therapies in Wet AMD
May 19th 2017EP. 10: Payer Coverage Decisions vs FDA Labeling in Wet AMD
May 19th 2017EP. 11: Access and Cost-Benefit Analyses for Wet AMD Treatments
May 19th 2017EP. 12: Payer Criteria for Anti-VEGF Therapies in Wet AMD
May 19th 2017EP. 13: Patient Cost Considerations in Wet AMD Management
May 19th 2017EP. 14: Payer Policy and Provider Choice in Wet AMD
